TTD DEADLINE MONDAY: ROSEN, A LEADING LAW FIRM, Encourages The Trade Desk, Inc. Investors to Secure Counsel Before Important April 21 Deadline in Securities Class Action
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of The Trade Desk, Inc. (NASDAQ: TTD) between May 9, 2024 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important April 21, 2025 lead plaintiff deadline.
SO WHAT: If you purchased Trade Desk Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Trade Desk class action, go to https://rosenlegal.com/submit-form/?case_id=35479 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) Trade Desk was experiencing significant, ongoing, self-inflicted execution challenges rolling out Kokai, a generative artificial intelligence ('AI') forecasting tool that enables users to more effectively deploy advertising spending, including transitioning clients to Kokai from Trade Desk's older platform Solimar; (2) such execution challenges meaningfully delayed the Kokai Rollout; (3) Trade Desk's inability to effectively execute the Kokai Rollout negatively impacted Trade Desk's business and operations, particularly revenue growth; and (4) as a result of the above, defendants' positive statements about Trade Desk's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Trade Desk class action, go to https://rosenlegal.com/submit-form/?case_id=35479 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
The multi-million-dollar investment provides NewAmsterdam Pharma with commercial capacity for fixed dose combination (FDC) of obicetrapib and ezetimibe to meet potentially high commercial demand. Piramal Pharma Solutions harnessed the strength of two additional facilities to efficiently produce the FDC, demonstrating the advantages of its integrated approach to development. MUMBAI, India, Aug. 21, 2025 /CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635), and NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) today announced the opening of a dedicated oral solid dosage (OSD) form suite at Piramal's facility in Sellersville, Pennsylvania, USA. As one of Piramal Pharma Solutions' focused drug product facilities, the Sellersville site provides comprehensive development and manufacturing services for various formulations, including several forms of OSDs. This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need. The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities. This includes a reconfiguration of existing space to create a dedicated OSD suite that will be used exclusively for fixed dose combination products. The new suite is designed for turnkey, multi-layer tablet production, equipped with advanced capabilities and technology to support granulation, compression, tableting, and coating. This suite will facilitate the production of NewAmsterdam Pharma's investigational FDC, a non-statin cholesterol medication to reduce LDL-C. Although the suite is essential to the FDC's production, the partnership between Piramal Pharma Solutions and NewAmsterdam Pharma extends beyond the Sellersville site. Piramal's Ahmedabad PPDS, India site played a crucial role in the product's development, while its Pithampur, India site provides dual sourcing support. "We are thrilled to expand our OSD production capabilities at the Sellersville facility with this new manufacturing suite," said Peter DeYoung, CEO, Piramal Global Pharma. "This addition will not only enhance our production capacity and speed, but reinforce our commitment to patient centricity, too." "By investing in Piramal Pharma Solutions' Sellersville facility, we are enabling the manufacture of FDC with exceptional precision and efficiency to meet the future commercial demand," said Douglas Kling, COO, NewAmsterdam Pharma. "We are excited to continue growing alongside our trusted partner, Piramal Pharma Solutions, and thrilled about the potential for our collaboration to benefit countless patients around the globe." Patients aren't the only beneficiaries of this investment. Over the next five years, the suite is expected to create more than 20 new jobs at the Sellersville site, further contributing to the local economy and workforce. This investment underscores the commitment to continuous improvement shared by Piramal Pharma Solutions and NewAmsterdam Pharma. By adding the new production suite, both companies can operate with greater efficiency and capacity, ultimately bringing the FDC product, if approved, to more patients in need. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. The Company seeks to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. About Piramal Pharma Solutions Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited. For more information visit: Piramal Pharma Solutions | LinkedIn| Facebook | X About Piramal Pharma Limited Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments. For more information, visit: Piramal Pharma | LinkedIn * Includes one facility via PPL's minority investment in Yapan Bio. Photo : : : : : View original content to download multimedia: SOURCE Piramal Pharma Solutions View original content to download multimedia:
Yahoo
17 minutes ago
- Yahoo
Warren Buffett's Berkshire Hathaway Just Exited Its Stake in T-Mobile and Loaded Up on an Artificial Intelligence (AI) Infrastructure Stock That's Risen 7,850% Since Its IPO
Key Points Berkshire exited the large mobile carrier T-Mobile, despite the fact the company has been executing well. Berkshire also disclosed a few mystery stocks that it purchased in the first quarter but chose to keep confidential until recently. One stock Berkshire bought is a traditional commodity company positioned as an artificial intelligence infrastructure play. 10 stocks we like better than Nucor › Warren Buffett's company Berkshire Hathaway recently filed its 13F form with the Securities and Exchange Commission (SEC), disclosing what stocks the large conglomerate held at the end of the second quarter. Using these filings, investors can see what stocks Berkshire bought and sold in a three-month window and get a rare glimpse into the minds of some of the smartest investors in the world. Berkshire has been a bit muted in recent quarters, choosing to pile into cash. But the company did make some notable moves in the second quarter, selling one decent-sized position and loading up on an artificial intelligence (AI) infrastructure stock. After a strong year, Berkshire calls it quits on T-Mobile The one position that Berkshire completely exited in the quarter was in the large mobile carrier T-Mobile (NASDAQ: TMUS). The company sold its entire position that had been valued at over $1 billion. Based on filings, Berkshire initiated its position in T-Mobile toward the end of 2020, and appears to have done well on the stock, which is up over 120% in the past five years. T-Mobile has also had a strong 2025, with the stock up about 16.5% (as of Aug. 15), and it recently reported strong second-quarter earnings. Diluted earnings per share of $2.84 rose about 14% year over year, while revenue jumped nearly 7%. Meanwhile, the company achieved some of its best-ever customer growth in the quarter, including 12% growth in its 5G broadband customer base, which is among the best in the industry. In 2023, T-Mobile initiated a dividend, which it has already grown significantly, and management's goal is to grow the quarterly dividend 10% annually. The team at Berkshire may simply be choosing to sell T-Mobile high. The stock is not far off from all-time highs and is now trading at a fairly high forward price-to-earnings ratio above 23. That's toward the higher end of where it has historically traded in recent years, and well above peers. The company has earned the valuation but Berkshire may see it as fairly priced right now. Berkshire has been secretly buying this AI infrastructure stock Many investors came into this 13F season excited about Berkshire once they realized that it would unveil some mystery stocks. Funds can request permission from the SEC to keep certain positions confidential for a certain amount of time. So Berkshire actually purchased Nucor (NYSE: NUE) in the first quarter, but the market only just found out about it in the company's second-quarter 13F. Berkshire's position in Nucor amounted to over $850 million at the end of the second quarter. Nucor is a steel company at its core. However, AI investors have gotten very interested because Nucor makes steel parts for data centers, which are in high demand to power and store all of the necessary data for large language models and AI applications. As a result of this and the way Nucor is positioned to support other burgeoning sectors, the stock has ripped close to 215% over the past five years and is up about 27% this year. Nucor's earnings through the first six months of the year are down significantly compared to last year, as the costs to make its steel products have risen. Investors were also disappointed by management's third-quarter guidance calling for "nominally lower" earnings, mainly due to margin compression in some of its segments. But the market expects President Donald Trump's 50% steel tariffs to benefit U.S. steel companies like Nucor, which will have an easier time raising prices because steel manufactured in other countries will be less competitive and more expensive. However, it could take time for higher prices to roll through. Nucor trades at about 17.5 times forward earnings, which I wouldn't necessarily call cheap in the steel sector. However, we have seen Buffett and his team get interested in U.S.-based commodity companies like oil and gas, perhaps due to a belief in increasing demand over time and a finite supply. Nucor could fit into this theme. Do the experts think Nucor is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nucor make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,070% vs. just 184% for the S&P — that is beating the market by 885.55%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool recommends T-Mobile US. The Motley Fool has a disclosure policy. Warren Buffett's Berkshire Hathaway Just Exited Its Stake in T-Mobile and Loaded Up on an Artificial Intelligence (AI) Infrastructure Stock That's Risen 7,850% Since Its IPO was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Why Iovance Biotherapeutics Stock Was Climbing Today
Key Points Iovance secured conditional approval for its cancer drug in Canada. This is pending the outcome of late-stage clinical trials. 10 stocks we like better than Iovance Biotherapeutics › A piece of good news on the regulatory front and a subsequent bullish analyst update were the factors driving Iovance Biotherapeutics (NASDAQ: IOVA) stock higher on Tuesday. The shares were almost 6% in positive territory in the middle of today's trading session, contrasting very well with the 0.5% slide of the S&P 500 index. Canada's thumbs-up for Amtagvi Just after market close Monday, Iovance announced that its cancer drug Amtagvi had been conditionally approved in Canada for treatment of certain forms of unresectable or metastatic melanoma. This green light from Health Canada, the country's medical regulator, is the biotech's first approval outside its native U.S. Final approval is conditional upon the results of late-stage clinical trials being conducted by the company. It added that it expects to authorize its first specialized treatment center in Canada in order to administer the medicine. It intends to do this at some point in the coming months. Iovance hopes to win approvals for Amtagvi in other jurisdictions with high instances of advanced melanoma specifically, and solid-tumor cancers generally. The drug earned approval from the U.S. Food and Drug Administration (FDA) for a similar indication in February 2024. It was the first cellular therapy to get the FDA's nod. Positive momentum Tuesday morning, H.C. Wainwright analyst Joseph Pantginis reiterated his buy recommendation on Iovance and his $20 per share price target. Not surprisingly, Pantginis' update was focused on the Health Canada move, according to reports. He wrote that it could be something of an inflection point for the healthcare company because Amtagvi will start producing a new revenue stream after final approval and boost the chances of a green light in other jurisdictions. Do the experts think Iovance Biotherapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Iovance Biotherapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,076% vs. just 184% for the S&P — that is beating the market by 892.04%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Was Climbing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
